{"denoms":[{"counts":[{"groupId":"BG000","value":"60"}],"units":"Participants"}],"groups":[{"description":"Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","id":"BG000","title":"Treosulfan and Fludarabine Conditioning"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"< 21 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"title":"Between 21 - 50 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Between 50 - 60 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Acute Lymphoblastic Leukemia(ALL)2nd/3rd remission"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"Acute Myelogenous Leukemia(AML)1st remission"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"AML, 2nd or greater remission."},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"AML, relapsed or primary refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Myelodysplastic Syndrome(MDS): Refract. Anemia(RA)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"MDS: RA with excess blasts in transformation"}],"paramType":"NUMBER","title":"Disease status at transplantation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"Low - AML/ALL in 1st rem., MDS with IPSS=0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"Standard (ALL or AML in 2nd or greater rem.)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"High -relapsed/refract. ALL/AML/MDS w/ IPSS>=2.5"}],"description":"Low-risk disease: AML or ALL in first remission, MDS with IPSS (International Prognosis Scoring System)=0; standard risk: ALL or AML in second or greater remission, MDS with IPSS 0.5-2; high risk: relapsed/refractory ALL or AML, MDS with IPSS\\>=2.5.","paramType":"NUMBER","title":"Disease risk group","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Good"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Intermediate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}]}],"title":"Poor"}],"description":"Good risk cytogenetics: t(8;21), t(15;17), or inversion 16 for AML, hyperdiploidy for ALL, -Y, del(5q), del(20q), or normal for MDS; poor risk: 11q23 abnormalities, monosomy 7, monosomy 5, deletion 5q, or abnormalities of 3q for AML, t(9;22) or extreme hypodiploidy for ALL, chromosome 7 abnormalities in MDS,$3 chromosome abnormalities for any disease type; Intermediate risk: all others","paramType":"NUMBER","title":"Cytogenetic risk group","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"1-2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}]}],"title":">=3"}],"description":"Risk of mortality after allograft (0 is lower risk, \\>=3 is higher risk)","paramType":"NUMBER","title":"Hematopoietic Cell Transplantation Comorbidity Index (HCT CI)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"HLA (human leukocyte antigen) -identical sibling"},{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"HLA-matched unrelated donor"}],"paramType":"NUMBER","title":"Donor type","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Bone marrow"},{"categories":[{"measurements":[{"groupId":"BG000","value":"53"}]}],"title":"Filgrastim-mobilized PBPC"}],"paramType":"NUMBER","title":"Stem cell source","unitOfMeasure":"participants"}]}